Drugs / [11C] (+)-4-propyl-(+)-4-propyl-9-hydroxynaphthoxazine (PHNO)
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT02959892 Background | Dec 2016 → May 2017 | — | Neurocrine Biosciences | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | [11C] (+)-4-propyl-(+)-4-propyl-9-hydroxynaphthoxazine (PHNO) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02959892 ↗ |
| Known as | PHNO | “[11C] (+)-4-propyl-(+)-4-propyl-9-hydroxynaphthoxazine (PHNO)” NCT02959892 ↗ |
| Route | Intravenous | “PHNO 180 MBq, injection, intravenously” NCT02959892 ↗ |